This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00097/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00097/identifier/genbank/
n7http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00097/identifier/uniprotkb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00097/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00097/identifier/pharmgkb/
n22http://www.rxlist.com/cgi/generic/
n21http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00097/identifier/drugbank/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00097
rdf:type
n3:Drug
n3:description
Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.
n3:dosage
n18:271B4505-363D-11E5-9242-09173F13E4C5 n18:271B4506-363D-11E5-9242-09173F13E4C5 n18:271B4507-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A: Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003 Sep 1;171(5):2305-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12928375 # Askling J, Erlandsson G, Kaijser M, Akre O, Ekbom A: Sickness in pregnancy and sex of child. Lancet. 1999 Dec 11;354(9195):2053. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10636378
n3:group
approved
n3:halfLife
The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).
n3:indication
For the treatment of female infertility
n3:manufacturer
n4:271B44FB-363D-11E5-9242-09173F13E4C5 n4:271B44FC-363D-11E5-9242-09173F13E4C5 n4:271B44FA-363D-11E5-9242-09173F13E4C5 n4:271B44FF-363D-11E5-9242-09173F13E4C5 n4:271B44FD-363D-11E5-9242-09173F13E4C5 n4:271B44FE-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00097 n19:DB00097
dcterms:title
Choriogonadotropin alfa
adms:identifier
n12:J00117 n13:DB00097 n14:P01233 n15:44087-1150-1 n23:PA164783947 n24:Choriogonadotropin_alfa
n3:mechanismOfAction
Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.
n3:packager
n4:271B44F9-363D-11E5-9242-09173F13E4C5 n4:271B44F7-363D-11E5-9242-09173F13E4C5 n4:271B44F8-363D-11E5-9242-09173F13E4C5 n4:271B44F6-363D-11E5-9242-09173F13E4C5
n3:patent
n21:6706681 n21:5767251
n3:routeOfElimination
One-tenth of the dose is excreted in the urine.
n3:synonym
Chorionic gonadotrophin beta subunit CG-beta Choriogonadotropin beta chain precursor
n3:volumeOfDistribution
* 5.9 ± 1.0 L
foaf:page
n17:choriogonadotropin-alfa.html n22:ovidrel.htm
n3:Molecular-Formula
n5:271B450C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B450B-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:G03GA08
n3:absorption
The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
177073-44-8
n3:category
n3:clearance
* 0.29 +/- 0.04 L/h [healthy down-regulated females]
n3:containedIn
n10:271B4504-363D-11E5-9242-09173F13E4C5 n10:271B4502-363D-11E5-9242-09173F13E4C5 n10:271B4503-363D-11E5-9242-09173F13E4C5 n10:271B4500-363D-11E5-9242-09173F13E4C5 n10:271B4501-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n5:271B4509-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n5:271B450A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4508-363D-11E5-9242-09173F13E4C5